secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0000950170-23-057420
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics cuts workforce 25%, extends cash runway into 2025; reports preliminary Q3 net loss $17-19M
--------------------------------------------------------------------------------

- Workforce reduced ~25%; restructuring cost ~$0.3M (nearly all cash) expected Q4 2023, complete by Q1 2024.
- Cash, cash equivalents and marketable securities ~$60.5M at Sept 30, 2023; cash runway extended into 2025.
- Preliminary Q3 net loss $17-19M (vs $16.2M in Q3 2022); nine-month net loss $53-55M.
- RT-102 Phase 2 starts Q4 2023; RT-111 Phase 1 topline Q1 2024; RaniPill HC Phase 1-ready H2 2024.
- RT-101 discontinued; RT-105 and RT-110 paused; new 33,340 sq ft lease in Fremont at $95,019/month base rent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/0000950170-23-057420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/rani-20231101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-057420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer